Literature DB >> 29426067

Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.

Nienke M Ter Haar1, Tamar Tak2, Michal Mokry1, Rianne C Scholman2, Jenny M Meerding2, Wilco de Jager1, Anouk Verwoerd2, Dirk Foell3, Thomas Vogl3, Johannes Roth3, Pieter H C Leliefeld2, Jorg van Loosdregt1, Leo Koenderman2, Sebastiaan J Vastert1, Sytze de Roock1.   

Abstract

OBJECTIVE: Neutrophils are the most abundant innate immune cells in the blood, but little is known about their role in (acquired) chronic autoinflammatory diseases. This study was undertaken to investigate the role of neutrophils in systemic-onset juvenile idiopathic arthritis (JIA), a prototypical multifactorial autoinflammatory disease that is characterized by arthritis and severe systemic inflammation.
METHODS: Fifty patients with systemic-onset JIA who were receiving treatment with recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) were analyzed at disease onset and during remission. RNA sequencing was performed on fluorescence-activated cell-sorted neutrophils from 3 patients with active systemic-onset JIA and 3 healthy controls. Expression of activation markers, apoptosis, production of reactive oxygen species (ROS), and degranulation of secretory vesicles from neutrophils were assessed by flow cytometry in serum samples from 17 patients with systemic-onset JIA and 15 healthy controls.
RESULTS: Neutrophil counts were markedly increased at disease onset, and this correlated with the levels of inflammatory mediators. The neutrophil counts normalized within days after the initiation of rIL-1Ra therapy. RNA-sequencing analysis revealed a substantial up-regulation of inflammatory processes in neutrophils from patients with active systemic-onset JIA, significantly overlapping with the transcriptome of sepsis. Correspondingly, neutrophils from patients with active systemic-onset JIA displayed a primed phenotype that was characterized by increased ROS production, CD62L shedding, and secretory vesicle degranulation, which was reversed by rIL-1Ra treatment in patients who had achieved clinical remission. Patients with a short disease duration had high neutrophil counts, more immature neutrophils, and a complete response to rIL-1Ra, whereas patients with symptoms for >1 month had normal neutrophil counts and an unsatisfactory response to rIL-1Ra. In vitro, rIL-1Ra antagonized the priming effect of IL-1β on neutrophils from healthy subjects.
CONCLUSION: These results strongly support the notion that neutrophils play an important role in systemic-onset JIA, especially in the early inflammatory phase of the disease. The findings also demonstrate that neutrophil numbers and the inflammatory activity of systemic-onset JIA are both susceptible to IL-1 blockade.
© 2018, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29426067     DOI: 10.1002/art.40442

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  13 in total

1.  Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.

Authors:  Lauren A Henderson; Kacie J Hoyt; Pui Y Lee; Deepak A Rao; A Helena Jonsson; Jennifer P Nguyen; Kayleigh Rutherford; Amélie M Julé; Louis-Marie Charbonnier; Siobhan Case; Margaret H Chang; Ezra M Cohen; Fatma Dedeoglu; Robert C Fuhlbrigge; Olha Halyabar; Melissa M Hazen; Erin Janssen; Susan Kim; Jeffrey Lo; Mindy S Lo; Esra Meidan; Mary Beth F Son; Robert P Sundel; Matthew L Stoll; Chad Nusbaum; James A Lederer; Talal A Chatila; Peter A Nigrovic
Journal:  JCI Insight       Date:  2020-03-26

Review 2.  Insights into rheumatic diseases from next-generation sequencing.

Authors:  Laura T Donlin; Sung-Ho Park; Eugenia Giannopoulou; Aleksandra Ivovic; Kyung-Hyun Park-Min; Richard M Siegel; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2019-06       Impact factor: 20.543

3.  Anakinra in Still's disease: a profile of its use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2018-10-31

Review 4.  Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease.

Authors:  Ricardo Grieshaber-Bouyer; Peter A Nigrovic
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

5.  Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease.

Authors:  Rachel A Brown; Maggie Henderlight; Thuy Do; Shima Yasin; Alexei A Grom; Monica DeLay; Sherry Thornton; Grant S Schulert
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

6.  Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

Authors:  Nienke M Ter Haar; E H Pieter van Dijkhuizen; Joost F Swart; Annet van Royen-Kerkhof; Ayman El Idrissi; Arjen P Leek; Wilco de Jager; Mark C H de Groot; Saskia Haitjema; Dirk Holzinger; Dirk Foell; Jorg van Loosdregt; Nico M Wulffraat; Sytze de Roock; Sebastiaan J Vastert
Journal:  Arthritis Rheumatol       Date:  2019-05-25       Impact factor: 10.995

Review 7.  Anakinra in children and adults with Still's disease.

Authors:  Sebastiaan J Vastert; Yvan Jamilloux; Pierre Quartier; Sven Ohlman; Lisa Osterling Koskinen; Torbjörn Kullenberg; Karin Franck-Larsson; Bruno Fautrel; Fabrizio de Benedetti
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

Review 8.  The Multi-Omics Architecture of Juvenile Idiopathic Arthritis.

Authors:  Xiaoyuan Hou; Huiqi Qu; Sipeng Zhang; Xiaohui Qi; Hakon Hakonarson; Qianghua Xia; Jin Li
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

9.  An Integrative Transcriptomic Analysis of Systemic Juvenile Idiopathic Arthritis for Identifying Potential Genetic Markers and Drug Candidates.

Authors:  Daeun Kim; Jaeseung Song; Sora Lee; Junghyun Jung; Wonhee Jang
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 10.  Update on Neutrophil Function in Severe Inflammation.

Authors:  Esmaeil Mortaz; Shamila D Alipoor; Ian M Adcock; Sharon Mumby; Leo Koenderman
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.